复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

休市中 07-24 16:08:05

56.100

-1.500

-2.60%

最高58.250	最低55.900	成交量41.09万
今开57.600	昨收57.600	日振幅4.08%
总市值305.75亿	流通市值195.23亿	总股本5.45亿
成交额2,326万	换手率0.12%	流通股本3.48亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":56.1,"timestamp":1784880485006,"preClose":57.6,"halted":0,"volume":410913,"delay":0,"changeRate":-0.026041666666666664,"floatShares":348000000,"shares":545000000,"eps":1.7475631377238936,"marketStatus":"休市中","change":-1.5,"latestTime":"07-24 16:08:05","open":57.6,"high":58.25,"low":55.9,"amount":23260580,"amplitude":0.040799,"askPrice":56.1,"askSize":2400,"bidPrice":56,"bidSize":8600,"shortable":3,"etf":0,"ttmEps":1.7480053483484428,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":7,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":57.6,"openAndCloseTimeList":[[1784856600000,1784865600000],[1784869200000,1784880000000]],"volumeRatio":0.7212938010941887,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"1145405224","title":"港股直击 | 生物医药股走强，康方生物涨近7%，荣昌生物涨超4%，泰格医药、诺诚健华涨近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145405224","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145405224?lang=zh_cn&edition=full","pubTime":"2026-07-22 10:11","pubTimestamp":1784686287,"startTime":"0","endTime":"0","summary":"7月22日，港股生物医药股走强，康方生物涨近7%，荣昌生物涨超4%，泰格医药、诺诚健华涨近3%，复宏汉霖、药明康德、君实生物涨超2%。消息面上，美国总统特朗普当地时间7月21日在社交媒体发文表示，自2026.8.1起，所有进口到美国的仿制药将在未来两年内继续适用零关税。两年期满后，相关产品将被征收100%的关税，期限为一年。此后，关税将进一步提高至200%。","market":"hk","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股直击 | 生物医药股走强，康方生物涨近7%，荣昌生物涨超4%，泰格医药、诺诚健华涨近3%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347","02359","09995","09926","01877","02696","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652137289","title":"复宏汉霖(02696.HK)授出合共413万份购股权及23万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2652137289","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652137289?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:31","pubTimestamp":1784298691,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000306701.USD","HK0000165453.HKD","02696","HK0000320223.HKD","HK0000306685.HKD","BK1161","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162074543","title":"复宏汉霖（02696.HK）授出413万份购股权及23万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=1162074543","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162074543?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:31","pubTimestamp":1784298675,"startTime":"0","endTime":"0","summary":"2026年7月17日，复宏汉霖董事会根据公司2025年H股购股权计划及2025年H股受限制股份单位计划，通过向合资格人士合计授出4,130,000份购股权及230,000份受限制股份单位的决议。– 其余230,000份购股权分四批按年度归属，80%与年度关键绩效指标挂钩，20%与市值目标挂钩，可在未达标情况下顺延一年，仍未达标则失效。在本次授予后，公司根据计划授权限额尚可授出23,748,088股H股；服务提供者分项限额下剩余7,222,422股H股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651410636","title":"复宏汉霖：HLX18临床试验中国境内首例患者给药完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2651410636","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651410636?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:03","pubTimestamp":1784192580,"startTime":"0","endTime":"0","summary":"7月16日，复宏汉霖（02696）发布公告，近日，公司自主研发的纳武利尤单抗生物类似药HLX18在多种已切除实体瘤患者中开展的国际多中心1期临床研究于中国境内完成首例患者给药。公司计划在条件具备后进一步在美国等地开展该国际多中心临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607163809105454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","HK0000320223.HKD","IBBQ","HK0000306685.HKD","BMED","HK0000320264.USD","02696","HK0000165453.HKD","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124290632","title":"复宏汉霖（02696）PD-1生物类似药HLX18全球多中心Ⅰ期试验在中国完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1124290632","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124290632?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:43","pubTimestamp":1784191382,"startTime":"0","endTime":"0","summary":"2026年7月16日，复宏汉霖发布自愿公告称，其自主研发的纳武利尤单抗生物类似药HLX18在多种已切除实体瘤患者中开展的国际多中心Ⅰ期临床研究，已于中国境内完成全球首例患者给药。公司计划在条件具备后，在美国等地继续推进该试验。2025年12月和2026年3月，HLX18分别在美国及中国境内获准开展针对多种实体瘤的Ⅰ期临床试验。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651417323","title":"复宏汉霖(02696.HK)：纳武利尤单抗生物类似药HLX18 (重组抗PD-1人源化单克隆抗体注射液)在多种已切除实体瘤患者中开展的国际多中心1期临床研究于中国境内完成全球首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2651417323","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651417323?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:32","pubTimestamp":1784190757,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000165453.HKD","HK0000306701.USD","HK0000320223.HKD","02696","HK0000320264.USD","HK0000306685.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651352154","title":"术后或可“去化疗” 复宏汉霖H药破解胃癌临床痛点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651352154","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651352154?lang=zh_cn&edition=full","pubTime":"2026-07-15 10:53","pubTimestamp":1784083980,"startTime":"0","endTime":"0","summary":"7月11日，由中国健康促进与教育协会主办、北京抗癌协会提供学术支持的“第一届胃癌围术期免疫治疗创新大会”召开。记者从大会现场获悉，对于可切除胃癌，围术期是提升治愈率、实现长期生存的关键窗口期，也是实现胃癌诊疗关口前移的重要阵地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153807210878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000320264.USD","HK0000320223.HKD","HK0000306685.HKD","BK1161","HK0000165453.HKD","02696","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651191714","title":"复宏汉霖H药全球布局加速兑现商业价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2651191714","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651191714?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:08","pubTimestamp":1783930080,"startTime":"0","endTime":"0","summary":"7月13日消息，在近日举行的“第一届胃癌围术期免疫治疗创新大会”期间，复宏汉霖执行董事、首席执行官朱俊在致辞中表示：“复宏汉霖长期深耕肿瘤等高发疾病领域，如今已将胃癌围术期免疫治疗方案切实带到患者身边。过去，胃癌患者承受着沉重的化疗负担；而今天，围术期患者已实现‘高质量去化疗’，迈向长生存的新阶段。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-07-13/doc-inihrxcc2264665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000320264.USD","HK0000306685.HKD","HK0000165453.HKD","BK1161","HK0000306701.USD","02696","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198039749","title":"复宏汉霖HLX37联合疗法获批开展Ⅰ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1198039749","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198039749?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:36","pubTimestamp":1783672588,"startTime":"0","endTime":"0","summary":"2026年7月10日，复宏汉霖生物技术股份有限公司发布自愿公告称，其自主研发的HLX37联合化疗或HLX43用于晚期/转移性实体瘤治疗的Ⅰ期临床试验申请已获国家药品监督管理局批准。公司计划在条件具备后于中国境内开展相关临床研究。公司称，截至公告披露日，全球尚无同类“HLX37联合化疗或HLX43”用药方案获批上市。复宏汉霖强调，HLX37及HLX43仍处于临床开发阶段，能否最终获批商业化尚存在不确定性。本次公告由复宏汉霖董事会主席张文杰签署并发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650183182","title":"复宏汉霖(02696.HK)：HLX37联合化疗或注射用HLX43用于晚期/转移性实体瘤治疗的 1期临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2650183182","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650183182?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:32","pubTimestamp":1783672375,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000320223.HKD","02696","HK0000306701.USD","BK1161","HK0000165453.HKD","HK0000320264.USD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649964779","title":"复宏汉霖(02696)：西妥昔单抗注射液生物类似药HLX05-N在转移性结直肠癌(mCRC)患者中的1期临床研究于中国境内完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2649964779","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649964779?lang=zh_cn&edition=full","pubTime":"2026-07-08 17:27","pubTimestamp":1783502848,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，本公司自主研发的西妥昔单抗注射液生物类似药HLX05-N在转移性结直肠癌患者中的1期临床研究于中国境内完成首例患者给药。本研究是一项在KRAS/NRAS野生型且BRAF V600E无突变的转移性结直肠癌参与者中，比较HLX05-N与美国及欧盟来源Erbitux联合化疗 治疗的多中心、随机、双盲、平行对照1期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1161","LU2322448791.USD","HK0000320264.USD","LU1992135399.USD","HK0000320223.HKD","HK0000306701.USD","LU2322448957.HKD","LU1992135472.HKD","LU2272731865.HKD","LU2272731782.SGD","PPH","02696","IBB","LU2272731600.USD","BK4588","XPH","HK0000165453.HKD","LU2473716301.USD","IE00B5TLWC47.USD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160015601","title":"复宏汉霖更新2026年6月股份变动月报表，总股本增至545,206,603股","url":"https://stock-news.laohu8.com/highlight/detail?id=1160015601","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160015601?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:17","pubTimestamp":1783329479,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司于2026年7月6日发布截至2026年6月30日的股份变动月报表。公告显示，公司注册股本已由上月底的543,494,853股增至本月底的545,206,603股。本月内，H股从346,074,397股增加至347,786,147股，新增部分为1,711,750股。非上市普通股数量维持197,420,456股不变。在激励计划方面，公司2025H股购股权计划本月内行权5,000股H股，所得资金为港币251,250。同时，28,750份购股权以及28,750份受限制股份单位已在本月内失效；另有1,706,750份受限制股份单位于本月内完成股份发行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648756745","title":"港股异动 | 复宏汉霖(02696)早盘涨近12% 汉斯状®获英国NICE推荐正式纳入NHS报销体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2648756745","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648756745?lang=zh_cn&edition=full","pubTime":"2026-07-02 11:12","pubTimestamp":1782961934,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖早盘涨近12%，截至发稿，涨7.07%，报68.95港元，成交额5273.15万港元。消息面上，据复宏汉霖官微消息，Accord Healthcare英国与公司近日宣布，H药 汉斯状已获英国国家卫生与临床优化研究所推荐正式纳入英格兰和威尔士国家医疗服务体系常规临床使用范围。随着NICE推荐正式落地及NHS挂网的完成，H药成为首个获得NICE批准、可在英格兰和威尔士用于ES-SCLC治疗的抗PD-1单抗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4543","NICE","HK0000306685.HKD","BK4566","02696","HK0000320223.HKD","BK4585","HK0000306701.USD","BK4588","HK0000320264.USD","VXUS","IE00BFMHRM44.USD","BK1161","HK0000165453.HKD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["07630","01651","06636","09637","01866","02723","03887","01286","00100","02696","01440","03388","06938","01133","BK4588","00412","02672","00863","01779","06656","BK4585","00600","03277","07688","01081","03625","09630","02526","01236","02726","02553","02335","01672","02670","03355","06106","02616","00340","01879","02142","02632","02729","03310","03661","06675","01511","06658","01191","02272","06872","00376","01956","01392","01021","01609","00068","07666"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2647153923","title":"复宏汉霖(02696.HK)：注射用HLX48用于晚期/ 转移性实体瘤治疗的1期临床研究于中国境内完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2647153923","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647153923?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:16","pubTimestamp":1782811018,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000320264.USD","HK0000320223.HKD","BK1161","HK0000306685.HKD","HK0000306701.USD","02696","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647734737","title":"港股异动 | 复宏汉霖(02696.HK)早盘涨超13% H药在欧盟获批新适应症 实现肺癌核心亚型一线治疗全覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=2647734737","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647734737?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:36","pubTimestamp":1782700612,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","HK0000165453.HKD","HK0000320264.USD","02696","HK0000306701.USD","HK0000320223.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647347370","title":"港股异动 | 复宏汉霖(02696)早盘涨超13% H药在欧盟获批新适应症 实现肺癌核心亚型一线治疗全覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=2647347370","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647347370?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:36","pubTimestamp":1782700612,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖早盘涨超13%，截至发稿，涨13.33%，报62.9港元，成交额3475.27万港元。这是H药在欧盟获批的第四项适应症，标志着其在欧盟市场实现了对肺癌核心亚型一线治疗的广泛覆盖。作为复宏汉霖全球化战略的核心产品，H药目前已在全球50个国家和地区获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460156.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320223.HKD","HK0000320264.USD","FSXEmain","VXUS","BK1161","BK4585","FESXmain","02696","HK0000306701.USD","BK4588","HK0000165453.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647545347","title":"复宏汉霖(02696)盘中拉升12.88% 自研HLX13完成美国首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2647545347","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647545347?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:34","pubTimestamp":1782700442,"startTime":"0","endTime":"0","summary":"金吾财讯 | 复宏汉霖 盘中持续拉升，最新报62.65港元，涨幅12.88%，成交额2623.06万港元。消息面上，该公司新近公告称，其自主研发的伊匹木单抗生物类似药HLX13一线治疗不可切除的晚期肝细胞癌患者的国际多中心1期临床研究完成美国首例患者给药。据悉，HLX13拟用于黑色素瘤、肾细胞癌、结直肠癌、肝细胞癌、非小细胞肺癌、恶性胸膜间皮瘤及食管鳞状细胞癌等原研药已获批的适应症。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984680","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","HK0000320223.HKD","HK0000320264.USD","HK0000306685.HKD","HK0000165453.HKD","BK1161","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646337092","title":"港股收评：香港恒生指数收跌1.76% “果链”舜宇光学科技跌超9%，鸿腾精密跌近8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646337092","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646337092?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:13","pubTimestamp":1782461622,"startTime":"0","endTime":"0","summary":"6月26日，香港恒生指数收跌1.76%，恒生科技指数收跌3.41%。苹果产业链公司跌幅居前，舜宇光学科技跌超9%，鸿腾精密跌近8%，瑞声科技跌近6%。微观交易层面，三季度港股面临IPO和解禁的流动性供给扰动。相较IPO而言，上市6个月之后的解禁潮对港股市场的负面影响相对更大。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/06/26161357594543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HHImain","LU0117841782.USD","03417","SG9999014880.SGD","BK4526","LU2476274308.USD","LU2125910849.SGD","LU1303224171.USD","LU2251237488.HKD","LU1046421795.USD","LU2039709279.SGD","00590","IE0032431581.USD","LU0054237671.USD","BK1587","LU0633140727.USD","SG9999018865.SGD","IE0009570106.USD","01810","LU0328353924.USD","LU0531970944.HKD","BABA","81024","03037","09626","09988","LU0828237510.HKD","LU1282649810.SGD","LU0873338254.USD","LU1048596156.SGD","LU0049112450.USD","LU0469268626.HKD","LU0545039389.USD","LU0572939691.SGD","BK1601","LU1316542783.SGD","LU0072462343.USD","LU0384037296.USD","LU0828238088.HKD","LU2462611646.USD","LU1808992512.USD","LU0819121731.USD","LU0181495838.USD","GB00BDT5M118.USD","LU1831875114.USD","LU2087589342.USD","IE00B0169N27.USD","LU0132412106.USD","LU0128522157.USD","02382","LU0553294199.USD","BK1609","LU0821914370.USD","LU0786609619.USD","LU0029875118.USD","BK4585","SG9999002463.SGD","BK4554","LU0572944931.SGD","LU0348783233.USD","LU3227948356.SGD","BABO","LU2097828714.EUR","LU2293587155.HKD","LU1688375341.USD","SG9999015986.USD","BK1575","LU2051468812.USD","LU0329678170.USD","LU0264606111.USD","SG9999013353.USD","LU0251144936.SGD","BK4535","LU0370786039.SGD","HK0000914686.HKD","SG9999014914.USD","LU0203345920.USD","LU0061477393.USD","BK4532","SG9999014906.USD","LU2488822045.USD","LU1282649067.USD","00700","LU1439103000.SGD","LU1515016050.SGD","LU0165289439.USD","LU1242518931.SGD","LU0823038988.USD","LU0463099449.HKD","LU1023057109.AUD","BK4565","LU1629966141.USD","02696","LU0051755006.USD","LU0348814723.USD","LU1196710351.USD","LU0640798160.USD","LU0196878994.USD","LU0737861772.HKD","LU0231483743.USD","LU2265009873.SGD","09115","LU2449936058.SGD","BK1523","LU2097828557.USD","LU0650527681.SGD","BK1233","BK4531","SG9999014674.SGD","LU0048580855.USD","BK1237","LU0047713382.USD","SGXZ81514606.USD","03033","LU0029874905.USD","LU1993786604.SGD","LU2045819591.USD","LU0348805143.USD","LU0823039010.USD","LU1981816686.USD","07226","LU2023250504.SGD","LU0949170772.SGD","09088","SG9999001226.SGD","82800","LU0823397103.USD","LU1770036033.HKD","LU2097828474.EUR","LU0107464264.USD","LU0577902611.USD","IE0031814852.USD","KBAB","LU0737861699.HKD","LU0261950983.USD","SGXZ99366536.SGD","LU2279701549.SGD","LU0819123356.HKD","03690","LU2125910500.SGD","LU0661504455.SGD","LU0345769631.USD","LU1868837722.USD","HK0000286598.CNH","IE00B067MR52.USD","LU0541501648.USD","BK1602","KJD","LU1733274473.HKD","BK4524","LU0499858602.USD","LU1734074674.USD","LU0541502299.USD","LU0588545904.SGD","LU0289960550.SGD","LU0345775950.USD","LU1228905037.USD","BK1588","LU0985320562.USD","LU0865486749.SGD","07200","SG9999001093.SGD","LU0117844026.USD","IE00BZ08YR35.GBP","BK4577","IE0008368742.USD","SG9999018857.SGD","LU1226288253.USD","IE00BQXX3D17.EUR","SG9999006514.SGD","LU0791591158.USD","LU1044876610.USD","LU0979878070.USD","LU0096374516.USD","LU0862451837.USD","BK1512","MCHmain","IE00BPRC5H50.USD","LU0642271901.SGD","LU0738911758.USD","LU0577902454.USD","SG9999015978.USD","LU0797268264.HKD","LU2362541513.USD","LU1328615791.USD","BK1140","LU0543330483.HKD","LU0456842615.SGD","LU0862451753.SGD","LU1823568750.SGD","LU0169518387.USD","BK4534","BK4504","BILI","BK1517","BK4505","IE00BQXX3C00.GBP","LU0823426308.USD","LU1196710864.SGD","SG9999001903.USD","SG9999017495.SGD","BK1516","LU0683595622.HKD","HK0000320223.HKD","00992","BK1508","LU1226288170.HKD","01024","LU0414403682.SGD","LU0607220059.USD","07300","LU0067412154.USD","LU1951186391.HKD","LU0106259558.USD","TCHmain","BK1615","BK4533","BK1526","LU0293314216.USD","LU0577902298.EUR","IE00B031J352.USD","LU0175139822.USD","BK4588","LU0708995153.HKD","02833","LU1770034418.SGD","LU2362540622.SGD","IE00BMCWC346.EUR","LU1804176565.USD","HK0001040143.USD","BK4122","BK1531","LU0878004406.USD","LU0287142896.SGD","LU0164865239.USD","LU0594300179.USD","LU0509642566.USD","LU1242518857.USD","LU2106854487.HKD","IE0008368411.USD","LU0823413660.USD","BK1583","LU2498475776.HKD","LU1883866441.USD","BK1586","LU1675838814.USD","LU0039217434.USD","LU0049853897.USD","LU0605514214.HKD","LU0348788117.USD","IE00B3M56506.USD","LU0611395673.USD","IE00BZ08YT58.USD","SG9999003461.SGD","LU0572940350.SGD","LU3063872942.SGD","SG9999007991.SGD","LU0675040207.SGD","LU2237443382.USD","ALBmain","HK0000306701.USD","09999","IE0034224299.USD","HK0000151867.HKD","SG9999014898.SGD","LU0127658192.USD","LU1051768304.USD","LU0540923850.HKD","BK1142","LU0348784397.USD","LU1814569148.SGD","LU0589944569.HKD","BK4579","83115","IE00BQXX3F31.USD","LU1267930227.SGD","IE00B97KM107.HKD","BK1114","BK1608","LU1880383440.USD","BK1504","LU0052756011.USD","LU1105468828.SGD","LU0784639295.USD","BK4581","BK4509","LU0140636845.USD","LU0791590937.USD","HK0001040168.HKD","LU0128522744.USD","LU1188198961.HKD","LU0210527791.USD","SG9999000327.SGD","002714","KSTmain","LU1691799644.USD","IE00B031HW06.USD","LU0672654166.SGD","81810","LU0593848301.USD","BK1545","LU0856984785.SGD","IE0001KFT4U8.USD","LU2237443622.USD","LU0831103253.SGD","BK1193","LU2177674079.SGD","LU0700851271.USD","06110","IE00B29SXG58.USD","LU0918141887.USD","LU0561508036.HKD","03423","01955","LU1813983027.USD","LU0886674414.USD","LU1366334578.USD","SG9999015952.SGD","03115","LU1064131003.USD","LU1152091168.USD","LU1810669033.SGD","LU0823041008.USD","LU1960683339.HKD","JD","LU0488056044.USD","IE00B8L5B284.USD","LU0738912210.USD","09618","LU0396098781.USD","LU2362541273.HKD","LU0210526637.USD","SG9999015945.SGD","IE00BVYPNQ40.USD","LU1152091754.HKD","LU1224709979.USD","LU2399975544.HKD","06088","LU1323998911.USD","HSI","LU2237443465.HKD","02800","LU1121112475.USD","LU1282648689.USD","SG9999000459.SGD","LU0164872284.USD","LU1196710195.USD","MIUmain","HK0000352382.USD","LU0228367735.SGD","SGXZ31699556.SGD","LU0348827113.USD","03067","BK4543","LU1568876335.HKD","LU0426417589.USD","LU0348767384.USD","LU0516423091.SGD","LU1718418525.SGD","LU0633140560.USD","LU0871576103.HKD","BK1604","LU0315179316.USD","LU0449509016.USD","LU0708995583.HKD","LU0320764599.SGD","LU0326950275.SGD","SG9999001846.SGD","LU0868486357.SGD","IE0003851619.USD","LU0214875030.USD","LU0502904849.HKD","LU0261947096.USD","03032","LU0828237940.HKD","LU0501845795.SGD","LU2133065610.SGD","LU0164880469.USD","LU1961090484.USD","LU0880133367.SGD","LU0128525689.USD","LU1228905540.USD","LNVGY","LU0588545490.SGD","IE00BF5LJ272.USD","LU1043141123.HKD","BK4587","LU2247934214.USD","LU0499858438.USD","LU0307460666.USD","LU0348816934.USD","03419","LU1044875133.USD","03088","BK4558","LU0011963245.USD","LU0163747925.USD","LU1504937902.USD","LU1720050803.USD","TCEHY","LU0314109678.HKD","BK4503","LU0070217475.USD","LU0203347892.USD","LU2097828805.USD","LU1226287792.SGD","BABW","LU0588546209.SGD","LU2257852520.SGD","IE00BZ08YS42.EUR","LU1251922891.USD","BK1591","BK4527","07500","LU1956131251.USD","LU2476274720.SGD","METmain","LU0516422952.EUR","LU2148611432.USD","XIACY","LU1226287529.USD","LU0455707207.USD","LU1439102457.SGD","LU0327786744.USD","LU0994945656.USD","SGXZ51526630.SGD","513600","BABX","LU0823397285.USD","SG9999000418.SGD","BK4501","LU1051769294.HKD","LU1282651048.USD","BK4548","SG9999002562.SGD","LU0235996351.USD","MPNGY","HMTD.SI","LU1785774172.SGD","BK4538","LU2148510915.USD","BK1590","BK4514","LU1769817179.HKD","LU2237443895.HKD","LU0449515922.USD","LU2242644610.SGD","02714","LU0634319403.HKD","SG9999006597.SGD","BK4220","BK1104","LU0516423174.USD","BK4502","LU1974910355.USD","LU1044874839.SGD","BK1607","LU1655091459.SGD","09067","HK0000306685.HKD","LU0228659784.USD","LU0149721374.USD","SG9999002828.SGD","LU1048588211.SGD","02837","IE00B543WZ88.USD","IE00BGV7N243.SGD","IE00B0169L03.USD","LU0043850808.USD","LU0608807433.USD","BK1521","LU0345769128.USD","LU1064130708.USD","LU0229945570.USD","LU0348766576.USD","LU0426412945.USD","HXXD.SI","07552","BABU","LU0918141705.HKD","LU1868837565.USD","BK1095","LU1282651121.HKD","HSTECH","LU0326948709.USD","LU2237443549.SGD","HK0000320264.USD","IE00B031HY20.USD","LU0651946864.USD","LU0054450605.USD","LU0210533765.USD","SG9999004220.SGD","LU0878005551.USD","LU0823413587.USD","IE0032834883.USD","BK1502","BK1589","LU0577902371.SGD","LU1235295612.USD","LU0823040885.USD","LU0251143458.SGD","LU0359201612.USD","LU0192582467.USD","LU2294711473.HKD","LU2251237306.USD","LU0310800965.SGD","LU2778985437.USD","IE00B5MMRT66.SGD","BK1224","BK4607","LU1043141396.HKD","LU1880383366.USD","LU1226288097.SGD","LU0608807946.USD","LU2317271919.USD","SG9999001689.USD","LU0348735423.USD","LU1003077747.HKD","LU0348783662.USD","LU2237443978.SGD","LU0173614495.USD","LU1725190679.HKD","IE00B0JY6N72.USD","BK4551","LU0345776255.USD","LU0516422366.SGD","BK1618","LU0080751232.USD","LU1807302812.USD","IE0003895053.USD","LU1211504680.USD","LU2226246903.HKD","LU1102505929.USD","LU1568876251.USD","80992","LU1481107354.HKD","LU1868838027.USD","LU0417516571.SGD","LU1048484197.HKD","LU1102505762.USD","BK4575","IE00BFMHRM44.USD","LU0329678337.USD","LU0441854154.USD","LU1115378108.SGD","LU1733274390.USD","LU1917777945.USD","LU1282649141.HKD","LU0648948544.HKD","LU1328277881.USD","LU0269904917.USD","LU0651947912.USD","LU0259732245.USD","HK0000352291.HKD","LU0543330566.HKD","NTES","BK1610","LU0254981946.USD","LU0348723411.USD","LU0143863784.USD","LU0211977185.USD","LU0545562505.USD","IE00BGHQDM52.EUR","SGXZ90724238.SGD","LU0106959298.USD","LU0516422440.USD","BK4085","LU0359202008.SGD","BK4614","HK0000914660.USD","LU0588545730.USD","LU0048597586.USD","LU0594300419.USD","LU0315178854.USD","LU0577902538.SGD","LU0149534421.HKD","BK1161","LU1794554557.SGD","IE00B8HQ1Z84.USD","LU2097828631.EUR","LU0417516738.SGD","LU0052750758.USD","LU0048388663.USD","LU0084288322.USD","LU1008478684.HKD","SG9999001069.SGD","LU0456846285.SGD","LU0211331839.USD","IE00BVYPNP33.GBP","LU1226287875.USD","LU1719994722.HKD","BK1170","LU1769817096.USD","LU1366334651.USD","BK1506","IE0003795394.USD","LU0359201885.HKD","LU1046422090.SGD","LU0417516902.SGD","LU0320764755.SGD","LU2152927971.USD","HK0000165453.HKD","LU0531971595.HKD","LU0348825331.USD","LU1224444064.USD","LU0890818403.SGD","LU0823426480.USD","LU0106252389.USD","LU0972618739.USD","LU0882747503.HKD","SG9999001051.SGD","LU0072913022.USD","LU0244354667.USD","BBYY","IE00BYV24P56.USD","LU1642822792.SGD","IE0008369823.USD","HTCD.SI","LU1235294995.USD","LU0188438112.USD","LU2008162690.USD","LU0320764243.SGD","LU0456827905.SGD","LU0143863198.USD","LU0431992006.USD","LU0898667661.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2646871144","title":"复宏汉霖(02696)：伊匹木单抗生物类似药HLX13一线治疗不可切除的晚期肝细胞癌(HCC)患者的国际多中心1期临床研究完成美国首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2646871144","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646871144?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:25","pubTimestamp":1782383143,"startTime":"0","endTime":"0","summary":"HLX13是本公司自主研发的伊匹木单抗生物类似药，拟用于黑色素瘤、肾细胞癌、结直肠癌、肝细胞癌、非小细胞肺癌、恶性胸膜间皮瘤及食管鳞状细胞癌等原研药已获批的适应症。2025年11月，HLX13一线治疗不可切除的肝细胞癌患者的国际多中心1期临床研究于中国境内完成首例患者给药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4006","HK0000306685.HKD","HK0000165453.HKD","HK0000320223.HKD","02696","HK0000306701.USD","HK0000320264.USD","HCC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0286},{"period":"1month","weight":-0.1095},{"period":"3month","weight":-0.3221},{"period":"6month","weight":-0.0435},{"period":"1year","weight":-0.1081},{"period":"ytd","weight":-0.0167}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事生物制药研发、生物制药服务及生物制药生产与销售的中国公司。该公司的主要产品包括汉曲优（注射用曲妥珠单抗）、汉奈佳（马来酸奈拉替尼片）、汉斯状（斯鲁利单抗注射液）、汉利康（利妥昔单抗注射液）、汉达远（阿达木单抗注射液）、汉贝泰（贝伐珠单抗注射液）等。该公司的产品主要应用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗、转移性非鳞状非小细胞肺癌、多关节型幼年特发性关节炎治疗等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.117695},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.008815},{"month":4,"riseRate":0.857143,"avgChangeRate":0.12138},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.033714},{"month":6,"riseRate":0.571429,"avgChangeRate":0.085211},{"month":7,"riseRate":0.428571,"avgChangeRate":0.041125},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}